FDA Eases Path for New Diabetes Behavioral Devices
Published Date: 7/24/2026
Rule
Summary
The FDA has officially placed the diabetes digital behavioral therapeutic device into Class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification took effect on July 24, 2026, with benefits starting from July 7, 2023, making it easier and potentially cheaper for makers to bring these devices to market.
Analyzed Economic Effects
5 provisions identified: 3 benefits, 2 costs, 0 mixed.
Special Controls: Clinical and Software Evidence
The final order requires design verification and validation that include clinical data from a "statistically and clinically justified sample size" and software verification, validation, and hazard analysis demonstrating the device performs as intended. The clinical data must validate the therapy model with a clinically defined endpoint and show the device does not adversely impact health outcomes.
Class II for Diabetes Therapy Software
The FDA classified the diabetes digital behavioral therapeutic device as Class II (special controls). The final order is effective July 24, 2026, and the classification was applicable on July 7, 2023. FDA says this classification will provide reasonable assurance of safety and effectiveness and may enhance patients' access by reducing regulatory burdens.
Enables 510(k) Predicate Pathway
By classifying this device into Class II via De Novo, FDA says that this device type can serve as a predicate for future devices. That means other device sponsors can use the less burdensome 510(k) process instead of De Novo or premarket approval for substantially equivalent devices.
510(k) Premarket Notification Still Required
FDA states that diabetes digital behavioral therapeutic devices remain subject to premarket notification under section 510(k). At this time, FDA has not determined that this device type is exempt from 510(k), so sponsors must submit a 510(k) to reasonably assure safety and effectiveness.
Labeling Must Include Clinical Summary and Limits
Labeling for these devices must include a summary of clinical testing and limiting statements. The label must say the device is not intended as a standalone therapy, is not a substitute for prescribed therapy or medication, should not be used by people with unstable psychiatric disorders, and is not intended to treat psychiatric disorders or symptoms.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-18432, Medical Devices; Cardiovascular Devices; Classification of the Temperature Regulation Device for Esophageal Protection During Cardiac Ablation Procedures
The Food and Drug Administration (FDA) is classifying the temperature regulation device for esophageal protection during cardiac ablation procedures into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the temperature regulation device for esophageal protection during cardiac ablation procedures. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
2026-18426, Medical Devices; General Hospital and Personal Use Devices; Classification of the Whole Room Microbial Reduction Device
The Food and Drug Administration (FDA) is classifying the whole room microbial reduction device into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the whole room microbial reduction device. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
2026-18433, Medical Devices; Cardiovascular Devices; Classification of the Mechanical Deviation Device for Esophageal Protection During Cardiac Ablation Procedures
The FDA is officially classifying a new device that protects the esophagus during heart procedures as a Class II device, meaning it’s safe and effective with some special rules. This change helps patients get access to this cool innovation faster by cutting down on red tape. The new classification took effect on September 10, 2026, but has been in place since September 6, 2023, making it easier and potentially cheaper for makers to bring this device to market.
Previous / Next Documents
Previous: 2026-14985, Medical Devices; Immunology and Microbiology Devices; Classification of the Over-the-Counter Test To Detect SARS-CoV-2 From Clinical Specimens
The FDA is officially putting over-the-counter COVID-19 tests into a safer, easier-to-manage category called Class II, starting July 24, 2026. This change helps make sure these tests work well and are safe, while also making it simpler for companies to bring new tests to you. If you’re a test maker or a user, expect better access and less red tape, with no extra costs announced.
Next: 2026-14987, Medical Devices; Orthopedic Devices; Classification of the Intraoperative Surgical Angle Measurement Tool
The FDA is officially putting the intraoperative surgical angle measurement tool into Class II, meaning it now has special safety rules but fewer red tape hurdles. This change helps make sure the tool is safe and effective while speeding up patient access to cool new tech. It affects device makers and hospitals, with the new rules effective July 24, 2026, and no big cost surprises expected.